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> 0.05, ANOVA). Postmortem evaluation
revealed that 2-3 hepatic veins were
transected by injury type 1, 1-2 portal vein
branches plus 1 hepatic vein were transected
by injury type 3 (LLL transection).
Conclusions: The hemorrhage severity of the
central stellate injury was inadequate, while
hemorrhage from excision of a proximal
branch of the portal vein appeared to be too
severe (i.e., the subjects died too quickly).

Near-transection of the hepatic LLL at its base
appeared to yield hemorrhage of appropriate
severity, as indicated by the 40% 1-hour
mortality and intermediate values for MAP,
blood loss, and other variables. Our plan is to
use this latter injury model in the development
of therapies for noncompressible truncal
hemorrhage. 
https://doi.org/10.32873/unmc.dc.gmerj.1.1.047
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Background: The use of exogenous
testosterone has become more prevalent in
recent years but the effects of such use in
regards to potential cerebrovascular disease
have yet to come to a conclusion. In this case
report, we discuss a patient who suffered
an ischemic stroke due to testosterone
supplementation.
Case presentation: A middle-aged
patient with history of hypertension and
hyperlipidemia that presented with falls,

difficulty performing simple tasks and slurred
speech. Patient had been taking testosterone
injections every 6 months for the prior 2 years
for loss of energy and reported low levels.
Lab work revealed a hemoglobin of 20 g/dL
and a hematocrit of 51.5%. MRI of the brain
showed a left striatocapsular ischemic infarct.
He was given the diagnosis of ischemic stroke
due to polycythemia and thrombus formation
secondary to testosterone supplementation.

association with ischemic stroke and there
may be an optimal level that is safe.
Conclusion: The risk of ischemic stroke may
be related to testosterone and DHT levels but
no clear guidelines exist on optimal levels
in supplementation. Thus, clinicians should
be aware of the potential risk and monitor
androgen and hematocrit levels. 
https://doi.org/10.32873/unmc.dc.gmerj.1.1.048

Discussion: Testosterone and
dihydrotestosterone (DHT) has both
protective and adverse effects. Both low and
high levels of testosterone and DHT have an
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Objective: To assess the effectiveness of
treatment for status epilepticus (SE) at UNMC
and determine patient health outcomes related
to the delayed control of seizures
Design/Methods: Retrospective chart
review was performed on 1565 adult
patients who underwent continuous video
electroencephalography (cvEEG) for
suspected seizures between January 1, 2012
and February 28, 2018.
Results: 49 patients had and were treated for
64 incidences of convulsive or nonconvulsive

SE recorded on cvEEG or clinical seizures
longer than 5 min which were documented by
a neurologist. Among 64 cases, 55 incidences
required the second AED treatment, and
40 out of 55 cases were treated with the
third AED subsequently. The mean seizure
detection-to-needle time for the first,
second, and third antiepileptic drugs were
167, 239, and 297 minutes, respectively.
Benzodiazepines were administered as the
first AED in only 46 % of all treated cases.
The duration of the hospital stays in patients
treated with the first AED within 60 min after
seizure detection was shorter compared to
those whose treatment was delayed (23.0 vs.

33.6 days, p=0.41). The mortality rate in the
former group was lower than that in the group
which did not receive AEDs within 60 min
(28.6 vs. 53.6%, p=0.02).
Conclusion: The current treatment approaches
for SE at UNMC are inefficient with
significant delay in delivery of medications
after seizure detection; they may contribute
to the prolonged hospital stay and increased
mortality. In order to improve patient care, the
existing protocol for the treatment of SE at
UNMC must be revised. 
https://doi.org/10.32873/unmc.dc.gmerj.1.1.049
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Background: VNS Therapy has demonstrated
overall cost savings in patients with drug-

51

resistant epilepsy. The overall goal of this
project is to evaluate the clinical and cost
effectiveness of the Aspire SR 106 VNS
(Vagus Nerve Stimulator) system, using
retrospective patient data. We anticipate
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the extra dimension of closed-loop
autostimulation in the Aspire 106 model will
demonstrate more efficient utilization of
health care resources.
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